-
Posted by
Two Blokes May 14 -
Filed in
Stock
-
1 view
Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flagship drug, but pivotal trial success remains uncertain, and skepticism persists among analysts. The company has a rock-solid balance sheet with some $1.75 billion in cash and no long-term debt.
